Baum Hedlund Aristei & Goldman changed its name to Wisner Baum in January 2023.

Cymbalta Unsealed Documents

Cymbalta Withdrawal Litigation Unsealed Documents

Declassified court documents obtained by Baum Hedlund during the course of the Cymbalta Withdrawal Litigation show that Eli Lilly and Company (the manufacturer of Cymbalta) was well aware of Cymbalta’s withdrawal risks, that they occur frequently and can be quite severe. Instead of being upfront about the risk, Lilly hid behind a misleading label, making it appear the risk was rare and symptoms mild.

Cymbalta Withdrawal Expert Trial Testimony and Exhibits

Expert Witness, Dr. Joseph Glenmullen, explains how Lilly obscured the risk of Cymbalta withdrawal.

Exhibit 001: Dr. Glenmullen Expert Witness Testimony

Exhibit 011: Clinical Report Form – Fluoxetine v. Sertraline and Paroxetine in Major Depression

Exhibit 022: Highlights of Prescribing Information for Cymbalta

Exhibit 069: Duloxetine v. Venlafaxine Extended Release in Treatment of Major Depressive Disorder

Exhibit 070: Cymbalta: Supportive Optional Document to Duloxetine Core Data Sheet Pre-Read Based on Clinical Trial Data in Adult Population

Exhibit 078: Journal of Clinical Psychiatry Supplement – Antidepressant Discontinuation Syndrome: Update on SSRIs 1997

Exhibit 093: Journal Affective Disorders – Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder 2005

Exhibit 110: Table 4.138: Treatment-Emergent Adverse Events MedDRA

Exhibit 111: Table 4.35: Treatment-Emergent Adverse Events AMDP-5

Exhibit 112: Table 4.20: Treatment-Emergent-Adverse-Events-AMDP-5

Exhibit 119: Biological Psychiatry – SSRI Discontinuation Syndrome: A Randomized Clinical Trial 1998

Exhibit 151: Illustration Brain Cell Sending and Receiving SSRI Messages (1 of 2)

Exhibit 152: Illustration Brain Cell Sending and Receiving SSRI Messages (2 of 2)

Exhibit 661: Journal of Clinical Psychiatry – Prospective Studies of Adverse Events Related to Antidepressant Discontinuation 2006

Cymbalta Withdrawal Factual Summary and Exhibits

These court documents show Lilly’s knowledge of Cymbalta withdrawal.

Appendix A: Plaintiffs’ Proposed Facts – Hagan-Brown, Ali v. Eli Lilly

Exhibit 01: Deposition of Michael J. Detke

Exhibit 02: Walter Deberdt Email Re: Comments on SUI Clinical Expert Report

Exhibit 03: Journal Clinical Psychiatry – Antidepressant Discontinuation Syndrome: Update on SSRIs (1997)

Exhibit 04: SSRI Discontinuation Syndrome: A Randomized Clinical Trial (1998)

Exhibit 05: Ali v. Eli Lilly Defendant’s Responses to Plaintiff’s Amended First Set of Requests for Admission

Exhibit 06: Brintnall & Nicolini – Prozac Pyramid Positioning / Message Development Research

Exhibit 07: Eli Lilly U.S. Strategic Pricing Study – Cymbalta (2002)

Exhibit 08: Lilly Internal Email – Perahia, Detke, Wohlreich RE: Discontinuation Data

Exhibit 09: Deposition of Madelaine Wohlreich (4/29/2015)

Exhibit 10: Cymbalta Patient Segmentation Study (2004)

Exhibit 11: Saavedra v. Eli Lilly – Declaration of Sarah Helgeson (2013)

Exhibit 12: Study: Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder (2005)

Exhibit 13: Ali v. Eli Lilly – Defendants’ Responses to Plaintiff’s First Set of Requests for Production of Documents

Exhibit 14: Hagan-Brown v. Eli Lilly – Defendants’ Responses to Plaintiff’s First Set of Requests for Production of Documents

Exhibit 15: Letter – Covington to Baum Hedlund RE: Hagan-Brown, Ali v Eli Lilly (March 2015)

Exhibit 16: Cymbalta Annex I – Summary of Product Characteristics

Exhibit 17: Side by Side Comparison of U.S. and European Labels for Cymbalta

Exhibit 18: Deposition of Sharon Hoog

Exhibit 20: Deposition of Dr. Navera Ahmed

Exhibit 21: Deposition of Matt Kuntz

Exhibit 22: Lilly Internal Email – Williams, Detke RE: Withdrawal Scale for Duloxetine

Exhibit 23: Duloxetine vs. Venflaxine Extended Release in the Treatment of Major Depressive Disorder (2002-2003)

Exhibit 24: Deposition of Madelaine Wohlreich (4/30/2015)

Exhibit 25: Boehringer Ingelheim Clinical Trial Protocol Revision A (June 2004)

Exhibit 26: Lilly Clinical Report Form – Fluoxetine v. Sertraline and Paroxetine in Major Depression: Comparison of Discontinuation-Emergent Symptoms

Exhibit 27: Table 4.35 Treatment-Emergent Adverse Events Collected by AMDP-5

Exhibit 28: Table 4.20 Treatment-Emergent Adverse Events Collected by AMDP-5

Exhibit 29: Lilly Internal Email – Perahia, Spencer, Brannan RE: HMBU Taper Period (Oct. 2002)

Exhibit 30: Clinical Study Report: Duloxetine Hydrochloride 60mg or 120mg Once Daily Compared with Placebo in Patients with Generalized Anxiety Disorder

Exhibit 31: Lilly Internal Email – Wang, Bump, Sakai, Detke, Stephens RE: Follow-up on PLR Meeting

Exhibit 32: Deposition of Christine Phillips PhD

Exhibit 33: Memo From Division of Medication Errors and Technical Support (2007)

Exhibit 34: Letter from Dr. Glenmullen to Matthew Leckman (Sept. 2014)

Exhibit 35: Dr. Glenmullen Addendum to Cymbalta Withdrawal General Causation Report May 2015

Exhibit 36: Louis Morris PhD Expert Report Cymbalta Discontinuation Litigation

Exhibit 37: Louis Morris PhD Supplemental Expert Report Cymbalta Discontinuation Litigation

Exhibit 38: Deposition of Dr. Michael Clark

Exhibit 39: Guidance for Industry Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products – Content and Format

Exhibit 40: Lilly Internal Email – Lee, Perahia RE: Question on DEAE’s (Dec. 2010)

Exhibit 41: Lilly Internal Email – Ziering, Perahia RE: Duloxetine/Cymbalta Withdrawal Question (Oct. 2006)

Exhibit 44: Lilly Internal Email – Miles, Detke, Kajdasz, Desaiah RE: Resubmitted. Your Review Required Again for Disclosure Approval Request

Exhibit 45: Study: A Randomized, Double-Blind Comparison of Duloxetine and Venlafaxine in the Treatment of Patients with Major Depressive Disorder (2008)

Exhibit 46: Declaration of Dr. Joseph Glenmullen (Aug. 2013)

Contact Us Today

No Fees Unless We Win

First Name
Please enter your first name.
Last Name
Please enter your last name.
+1 Phone
Please enter your phone number.

This isn't a valid phone number.
Email
Please enter your email address.

This isn't a valid email address.
City
Please enter your city.
State
Please make a selection.
Subject
Please make a selection.
Are you a new client?
Please make a selection.
Message
Please enter a message.

Pharmaceutical Settlement $105 Million
Paxil Pediatric Class Action $63 Million
Third-Party Payer Class Action $40 Million
Defective Drug Class Action $28 Million
Celexa-Lexapro Pediatric Class Action $10 Million
Drug Injury $9 Million

/

Best Law Firms 2023
A ranking in The U.S. News – Best Lawyers® “Best Law Firms” is widely regarded by both client and legal professionals as a significant honor. It is considered the most reliable, unbiased source of legal referrals anywhere.
The Truck Safety Coalition
Wisner Baum is proud to be a sponsor of The Truck Safety Coalition, a a group of caring individuals dedicated to reducing the number of deaths and injuries caused by truck-related crashes. Our support enables them to help families and save lives.
California Powerhouse
Law360 recognizes law firms that have a strong regional presence, working on important matters within their home state. “[Wisner Baum] possesses a David v. Goliath-sized slingshot while seeking justice for everyday citizens it believes were harmed or killed through corporate wrongdoing.”
Elite Trial Lawyers
NLJ and American Lawyer Media honor law firms and attorneys as Elite Trial Lawyers for their cutting-edge legal work on behalf of plaintiffs in practice areas ranging from mass torts to securities litigation.
Listed in Best Lawyers
Best Lawyers is the oldest and most respected peer-review publication in the legal profession. A listing in Best Lawyers is widely regarded by both clients and legal professionals as a significant honor, conferred on a lawyer by his or her peers.
AV Top Ranked Law Firm
Less than one-half of one percent of firms across the nation have achieved this ranking. A firm must have a high percentage of lawyers who have achieved the prestigious AV® Preeminent rating by Martindale-Hubbell®.
Verdicts Hall of Fame
The National Law Journal inducted Wisner Baum into the Verdicts Hall of Fame for obtaining the $2 billion landmark verdict in the Roundup cancer case of Pilliod et al. v. Monsanto. The verdict was #1 in California and #2 in the U.S. in 2019 and is #9 in American history.
Super Lawyers
Super Lawyers is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high-degree of peer recognition and professional achievement.
National Trial Lawyers Top 100
The National Trial Lawyers Top 100 recognized the law firms of Wisner Baum, the Miller Firm and Audet & Partners with the 2019 Trial Team of the Year award (in the Mass Torts category) for their work in the groundbreaking case of Dewayne “Lee” Johnson v. Monsanto Company.
AV Preeminent Peer Review Rated
An AV® rating reflects an attorney who has reached the heights of professional excellence. The rating signifies the highest legal ability, and very high adherence to professional standards of conduct, ethics, reliability, and diligence.
Avvo 10.0 Rating
Wisner Baum is proud to have all of its lawyers listed in Avvo, a legal directory connecting people in need of legal services with lawyers and connecting lawyers to lawyers. Eight of our attorneys have earned a 10.0 perfect rating with Avvo.
Top Jury Verdict in
CA and USA
TopVerdict.com ranks our $2 billion verdict in Pilliod et al. v. Monsanto as the biggest verdict in California and the second largest verdict in the U.S. in 2019. It is the ninth largest verdict in U.S. history.
Lawdragon 500 Leading Plaintiff Consumer Lawyers
Published annually, the Lawdragon 500 Leading Plaintiff Consumer Lawyers list recognizes the “best of the best” in this area of the law through nominations, research, and review by a board of their peers.
Product Liability Practice Group of the Year
In 2020, Law360 honored the law firms ”behind the litigation wins and major deals that resonated throughout the legal industry.” It recognized our success in several landmark cases.
Top Personal Injury Jury Verdict in California
In 2018, our $289 million Johnson v. Monsanto verdict was the largest personal injury verdict in California. TopVerdict.com also ranked it #2 among all verdicts in California and #10 in the nation.
Bar Register of Preeminent Lawyers
The Bar Register is the definitive guide to the most distinguished law firms in America. It includes only those select law practices that have earned the highest rating in the Martindale-Hubbell Law Directory and have been designated by their colleagues as preeminent in their field.

/

Firm Reviews

What Our Clients Are Saying

I Can’t Imagine a Better Law Firm
“Multiple lawyers recommended Wisner Baum to me and I have been consistently impressed with the quality of their work.”
- Best Law Firms Survey
They Are About Changing the Systems...
“Wisner Baum are not only amazing attorneys but more importantly, they are activists. They are about changing the systems which got us into trouble in the first place. They understand their role in the process of making change.”
- Kim Witczak
Top Legal Minds in the Country
“The Wisner Baum firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.”
- From Best Lawyers® Best Law Firms
Diligent & Professional Representation
“Thanks to your efforts I was able to recover from a tragic experience and turn my life around for the best.”
- W.T.
Our Best Interest Was Always Number One on Your List
“A special thank you to your Spanish-speaking staff for the extra effort put into this case. The language barrier was never a problem, and we are so very thankful to them. Your name holds much respect in our family.”
- G.C. & C.C

/

Read More